AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

DATROWAY ® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer. TROPION-Lung02 and TROPION-Lung04 phase 1b ...

DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer Jun. 24, 2025 7:00 AM ET AstraZeneca PLC (AZN) Based on TROPION-Lung05 results ...

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Business Wire Jun 23, 2025 ...

Datroway secured the EGFR-mutated non-small cell lung cancer indication after the companies had withdrawn an earlier application in nonsquamous NSCLC following a phase 3 overall survival miss. 4.

The lung-cancer drug Datroway, being jointly developed by AstraZeneca and Daiichi Sankyo, has been approved in the U.S. to treat adult patients with non-small cell lung cancer.

Datroway® approved in the US as first TROP2 directed therapy for patients with previously treated advanced EGFR-mutated non-small cell lung cancer. News release. Daiichi Sankyo.